Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage biotechnology leader developing novel stem cell-based delivery systems for oncolytic virotherapies. This page provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in cancer treatment innovation.
Access comprehensive coverage of CLDI's progress across its therapeutic platforms, including CLD-101 for high-grade gliomas and RTNova for metastatic cancers. Our curated news collection features verified updates on trial milestones, regulatory filings, and peer-reviewed research findings essential for understanding the company's trajectory.
Key updates include developments in Phase 1b/2 clinical trials, technology licensing agreements, and advancements in systemic virotherapy delivery systems. All content undergoes rigorous verification to ensure accuracy in reporting complex biopharmaceutical developments.
Bookmark this page for streamlined access to Calidi's latest press releases, investor communications, and analysis of its stem cell platform's potential across oncology and regenerative medicine applications. Stay informed about critical developments in next-generation cancer therapies through our maintained news repository.
Calidi Biotherapeutics (NYSE: CLDI) has announced IL15 superagonist as the first payload for its systemic antitumor virotherapy platform, RTNova. The announcement was made at the AACR Annual Meeting on April 27, 2025.
The RTNova platform utilizes an engineered vaccinia virus designed for tumor-selective targeting and produced in an enveloped form that enables survival in bloodstream circulation to reach metastatic tumor sites. Preclinical data demonstrates that the platform's ability to express IL15 superagonist specifically in tumor microenvironments significantly increases complete tumor elimination responses after a single systemic administration.
This advancement represents a significant step in treating metastatic cancers, as it overcomes the limitations of traditional intratumoral oncolytic viruses by enabling systemic administration. The platform can also be adapted to deliver various therapeutic payloads, allowing customized treatment approaches for different tumor types.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has granted an inducement non-qualified stock option to its newly appointed CEO, Eric Poma, Ph.D. The stock option allows for the purchase of 726,412 shares at an exercise price of $0.469 per share, based on the closing price on April 22, 2025.
The stock options feature a four-year vesting schedule, with 25% vesting on April 22, 2026, and the remaining portion vesting in equal monthly installments through April 22, 2029. This grant was approved by the Company's Compensation Committee and Board of Directors in accordance with Section 711 of NYSE American Company Guide.
Calidi Biotherapeutics (NYSE American: CLDI) has announced a significant leadership transition, with Eric Poma, Ph.D. succeeding Allan Camaisa as CEO and Board Director, effective April 22, 2025. Camaisa will remain on the Board.
Dr. Poma brings over 30 years of biopharmaceutical industry experience, notably as CEO of Molecular Templates where he raised $250+ million in equity financing and secured $150+ million through strategic agreements with Takeda, Vertex, and BMS. His background includes roles at Innovive Pharmaceuticals, Imclone Systems, and as a Healthcare & Biotechnology Analyst.
The transition comes as Calidi, a clinical-stage biotechnology company, advances its systemic enveloped virotherapy platform, including preparations for a dose escalation trial of CLD-201 in adult patients with solid tumors. The company continues development of its CLD-400, CLD-101, and CLD-201 programs.
Calidi Biotherapeutics (NYSE American: CLDI) announces an exclusive live investor webinar scheduled for April 24, 2025, at 4:15 p.m. ET. The event will feature presentations by newly appointed Chief Medical Officer Dr. Guy Travis Clifton and CFO Andrew Jackson.
Dr. Clifton, a surgical oncologist and U.S. Army Colonel with 17 years of experience in oncology drug development, will discuss Calidi's stem cell-based delivery platforms for enhanced cancer treatment. The webinar will highlight the company's progression following FDA clearance of their IND application for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, focusing on breast cancer, head & neck cancer, and soft tissue sarcoma.
The presentation will also cover other lead programs including CLD-400 (RTNova) for metastatic and lung cancer, and CLD-101 for high-grade gliomas. A Q&A session will follow the presentation.
Calidi Biotherapeutics (NYSE American: CLDI) has received FDA clearance for its Investigational New Drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy targeting solid tumors in adults. The therapy will focus on treating breast cancer, head & neck cancer, and soft tissue sarcoma.
The IND application included preclinical data showing CLD-201's potential to evade viral inactivation by the patient's immune system and effectively target cancer cells. The innovative treatment combines adipose tissue-derived stem cells with oncolytic vaccinia virus, representing a unique approach in cancer therapy.
Upcoming clinical trials will evaluate the safety, tolerability, and preliminary efficacy of CLD-201 in patients with these difficult-to-treat tumors, addressing significant unmet medical needs.
Calidi Biotherapeutics (NYSE: CLDI) has appointed Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. This announcement comes as the company advances its targeted antitumor virotherapies through clinical development.
Dr. Clifton brings over 17 years of experience in drug development, early phase trials, and cancer immunotherapy. He previously served as CMO at Parthenon Therapeutics/Incendia Therapeutics and has been a practicing surgical oncologist in the US Army since 2013. His expertise includes advising over 20 companies and authoring more than 80 peer-reviewed publications.
The appointment aligns with Calidi's recent IND filing for a dose escalation trial of CLD-201 in adult patients with solid tumors. The company is developing two platforms: a systemic approach using extracellular enveloped viruses to target metastatic tumors, and an intratumoral approach using stem cells to protect and enhance virotherapy potency.
Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has successfully closed its previously announced registered direct offering and concurrent private placement, raising $3.9 million in gross proceeds. The transaction includes:
- 3,325,000 shares of common stock
- Pre-funded warrants for 2,728,000 shares at $0.001 exercise price
- Series G warrants for 6,053,000 shares at $0.6954 exercise price
The combined offering price was set at $0.65 per share. The Series G warrants will be exercisable after six months and expire seven and a half years following the initial exercise date. Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent. The company plans to use the proceeds for working capital, general corporate purposes, and advancing its pre-clinical and clinical programs.
Calidi Biotherapeutics (NYSE: CLDI) reported its Q4 and full-year 2024 financial results, highlighting significant progress across its three therapeutic platforms. The company demonstrated success in delivering gene therapy payload to tumors using its systemic antitumor virotherapy platform.
Key developments include: filing an IND for CLD-201 Phase 1 trial for multiple solid tumors in March 2025, advancing recruitment for a Phase 1 trial at Northwestern University for newly diagnosed high-grade glioma patients, and enrolling 14 patients in a City of Hope Phase 1 trial for recurrent high-grade glioma.
Financial results show a Q4 2024 net loss of $4.1 million ($0.27 per share), compared to $8.2 million in Q4 2023. Full-year 2024 net loss was $23.8 million ($2.97 per share). The company ended 2024 with $9.6 million in cash.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
